Connect with us

Hi, what are you looking for?

Business

GSK sues Pfizer over patents for RSV vaccine

GSK alleges Pfizer infringed four of its patents in developing a competing RSV vaccine
GSK alleges Pfizer infringed four of its patents in developing a competing RSV vaccine - Copyright GETTY IMAGES NORTH AMERICA/AFP/File SPENCER PLATT
GSK alleges Pfizer infringed four of its patents in developing a competing RSV vaccine - Copyright GETTY IMAGES NORTH AMERICA/AFP/File SPENCER PLATT

GlaxoSmithKline sued Pfizer on Wednesday over patent infringement, alleging the US drugmaker’s RSV vaccine steals key elements of the British company’s version.

The case, filed in federal court in the state of Delaware, pits the producers of the only two approved vaccines for respiratory syncytial virus (RSV) against each other.

The United States on May 3 approved GSK’s Arexvy as the first vaccine for RSV; that was followed on May 31 with US approval of Pfizer’s Abrysvo. Both vaccines have since been approved by the European Union. 

“Upon information and belief, Pfizer knowingly uses GSK’s claimed inventions in Abrysvo without permission,” said the GSK complaint.

The complaint describes Arexvy as “the result of more than 15 years of research and development by GSK scientists,” adding that Pfizer’s program on an RSV vaccine began “no earlier than 2013.”

The lawsuit lists four GSK patents granted by US officials between 2013 and 2023 that Pfizer is alleged to have infringed.

The suit seeks compensation for lost profits and royalties and a permanent ban on Pfizer selling the product in the United States.

RSV is a widespread, highly contagious pathogen most known for causing bronchiolitis — an irritation and inflammation of the small airways — in young children, especially in winter.

It also infects adults and can become dangerous in the elderly, who may develop pneumonia.

Pfizer did not immediately respond to a request for comment.

AFP
Written By

With 2,400 staff representing 100 different nationalities, AFP covers the world as a leading global news agency. AFP provides fast, comprehensive and verified coverage of the issues affecting our daily lives.

You may also like:

Tech & Science

Vodafone may sell its Italian unit to Swisscom after rejecting merger offers from French billionaire Xavier Niel's Iliad group - Copyright AFP/File Jim WATSONBritish...

Business

The IATA says 'on average a person would have to travel by air every day for 103,239 years to experience a fatal accident' -...

World

When people make decisions, dopamine seems to closely follow and react to whether the current offer is better or worse than the previous one,...

World

Germany is Ukraine's second-biggest weapons donor behind only the United States, with France trailing far behind, according to figures compiled by the Kiel Institute...